Stay updated with breaking news from Ipid Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair of early studies.
Certain polyunsaturated fatty acids (PUFAs) may have a favorable effect on disease progression and survival for patients with amyotrophic lateral sclerosis.
The FDA has given the new low dose of colchicine a broad indication for use in atherosclerotic cardiovascular disease, but how will the drug actually be used in clinical practice?
Both Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin) were approved for children aged 10 years and older.
The question of whether a multidisciplinary post-stroke care program should be judged on its ability to prevent major cardiovascular events at 1 year was raised after a trial showed no benefit.